Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Dicato on Agents to Treat Thrombocytopenia for Patients With Cancer

Published: Wednesday, Jul 20, 2016


Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.

Rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) are currently available for patients, Dicato explains. However, these agents have been criticized due to a lack of data demonstrating efficacy and safety.

An advantage is that patients do not need to undergo platelet testing after receiving these oral treatments, he adds.
 

Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.

Rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) are currently available for patients, Dicato explains. However, these agents have been criticized due to a lack of data demonstrating efficacy and safety.

An advantage is that patients do not need to undergo platelet testing after receiving these oral treatments, he adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x